Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[From genomics to therapeutics].

A Kahn1

  • 1Institut Cochin de Génétique Moléculaire, Unité 129 de l'Institut National de la Santé et de la Recherche Médicale, CHU Cochin Port-Royal, 24, rue du Faubourg Saint Jacques-75014 Paris.

Bulletin De L'Academie Nationale De Medecine
|March 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myotube-specific activity of the human aldolase A M-promoter requires an overlapping binding site for NF1 and MEF2 factors in addition to a binding site (M1) for unknown proteins.

Journal of molecular biology·1995
Same author

Glucose, growth hormone, cortisol, and insulin responses to glucagon injection in normal infants, aged 0.5-12 months.

The Journal of clinical endocrinology and metabolism·1995
Same author

Overproduction of a truncated hepatocyte nuclear factor 3 protein inhibits expression of liver-specific genes in hepatoma cells.

Molecular and cellular biology·1995
Same author

Functional dissection of the brain-specific rat aldolase C gene promoter in transgenic mice. Essential role of two GC-rich boxes and an HNF3 binding site.

The Journal of biological chemistry·1995
Same author

Gene delivery into the central nervous system by nasal instillation in rats.

Gene therapy·1995
Same author

Reduction in obstructive breathing events during body rocking: a controlled polygraphic study in preterm and full-term infants.

Pediatrics·1995
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Human genome sequencing offers hope for personalized medicine and improved therapies. However, challenges from prevalent diseases and economic factors necessitate cautious optimism regarding a disease-free future.

Area of Science:

  • Genomics and Medicine
  • Translational Bioinformatics

Context:

  • The imminent completion of human genome sequencing presents significant opportunities for medical advancement.
  • Current medical paradigms are shifting towards personalized approaches based on individual genetic profiles.

Purpose:

  • To critically evaluate the realistic prospects and potential challenges associated with human genome sequencing in medicine.
  • To temper expectations of a disease-free future while acknowledging advancements in targeted therapies.

Summary:

  • Human genome sequencing promises personalized medicine, tailoring treatments for maximal efficacy and minimal toxicity.
  • Anticipated progress in chemotherapy and biological therapies is significant.
  • Major challenges include the persistence of diseases in developed nations and economic constraints in developing countries.

Related Experiment Videos

Impact:

  • While a disease-free world remains unlikely, genome sequencing will likely refine therapeutic strategies.
  • Healthcare systems must address the complexities of integrating genomic data into clinical practice.
  • The need for medical professionals will persist due to the ongoing prevalence of diseases.